Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Blood glucose criteria must be met~* Previously responded, as defined by the protocol, to treatment with pioglitazone or rosiglitazone~* Body mass index (BMI) in the range 22-45~Exclusion Criteria:~* Type 1 diabetes~* Pregnancy or lactation~* Evidence of serious cardiovascular complications~* Evidence of serious diabetic complications~* Laboratory value abnormalities as defined by the protocol~* Known sensitivity to pioglitazone~* Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Vildagliptin 50 mg qd + pioglitazone 45 mg qd (Type: EXPERIMENTAL): Vildagliptin 50 mg qd + pioglitazone 45 mg qd for 24 weeks
- Vildagliptin 50 mg bid + pioglitazone 45 mg qd (Type: EXPERIMENTAL): Vildagliptin 50 mg bid + pioglitazone 45 mg qd for 24 weeks
- Vildagliptin placebo + pioglitazone 45 mg qd (Type: PLACEBO_COMPARATOR): Vildagliptin placebo + pioglitazone 45 mg qd for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).